On Thursday, Viking Therapeutics (NASDAQ:VKTX) shares were initiated with an Overweight rating by an investment firm, projecting a significant potential for growth. The firm has set a price target of $105 for the biopharmaceutical company's stock.
The positive outlook is based on the promising Phase 2 data for VK2735 and VK2809, Viking's investigational therapies for obesity and NASH/MASH, respectively. According to the firm, these results indicate that the treatments may offer a best-in-class profile within their markets.
The firm's analyst pointed out that the two drug candidates are poised to tap into blockbuster market opportunities. The anticipation of near-term updates on these drugs is expected to contribute to further upside for Viking Therapeutics.
The current price target of $105 reflects the firm's confidence in Viking's growth trajectory and the commercial prospects of its pipeline products. This target suggests a significant increase from the stock's previous levels.
Viking Therapeutics is currently focused on the development of novel therapies for metabolic and endocrine disorders. The company's progress and future updates are likely to be closely monitored by investors following this new coverage.
In other recent news, Viking Therapeutics has made significant strides in its drug development and financial standing. The biopharmaceutical company's preclinical trials showcased the potential of its dual agonists in the treatment of obesity and metabolic diseases, with significant reductions in body weight and food intake observed in animal models. Analysts at H.C. Wainwright and Truist Securities maintained their Buy ratings on Viking, with price targets of $90 and $120 respectively, reflecting confidence in the company's research outcomes.
Viking's Phase 2b VOYAGE study of VK2809 reported promising results in treating patients with non-alcoholic steatohepatitis (NASH), with significant reductions in liver fat content and improvements in fibrosis. The company's Phase 2 VENTURE study of VK2735, aimed at treating obesity, also met its primary and secondary endpoints, demonstrating significant reductions in body weight.
The company also reported successful outcomes from a Phase 1 trial of an oral tablet formulation of VK2735 and plans to proceed with further development later this year. A public stock offering was completed, raising approximately $630 million, strengthening Viking's financial position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.